Blood Metabolites Associate with Prognosis in Endometrial Cancer

Elin Strand, Ingvild L. Tangen, Kristine E. Fasmer, Havjin Jacob, Mari K. Halle, Erling A. Hoivik, Bert Delvoux, Jone Trovik, Ingfrid S. Haldorsen, Andrea Romano, Camilla Krakstad*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Web of Science)

Abstract

Endometrial cancer has a high prevalence among post-menopausal women in developed countries. We aimed to explore whether certain metabolic patterns could be related to the characteristics of aggressive disease and poorer survival among endometrial cancer patients in Western Norway. Patients with endometrial cancer with short survival (n = 20) were matched according to FIGO (International Federation of Gynecology and Obstetrics, 2009 criteria) stage, histology, and grade, with patients with long survival (n = 20). Plasma metabolites were measured on a multiplex system including 183 metabolites, which were subsequently determined using liquid chromatography-mass spectrometry. Partial least square discriminant analysis, together with hierarchical clustering, was used to identify patterns which distinguished short from long survival. A proposed signature of metabolites related to survival was suggested, and a multivariate receiver operating characteristic (ROC) analysis yielded an area under the curve (AUC) of 0.820-0.965 (p

Original languageEnglish
Article number302
Number of pages15
JournalMetabolites
Volume9
Issue number12
DOIs
Publication statusPublished - Dec 2019

Keywords

  • metabolomics
  • biomarker
  • endometrial cancer
  • VISCERAL ADIPOSE-TISSUE
  • NEOADJUVANT CHEMOTHERAPY
  • METABOLOMIC SIGNATURE
  • BIOMARKERS
  • METHIONINE
  • CELLS
  • SERUM
  • GENE

Cite this